High-sensitivity troponin I for risk stratification in normotensive pulmonary embolism.

While numerous studies have confirmed the prognostic role of high-sensitivity troponin T (hsTnT) in pulmonary embolism (PE), high-sensitivity troponin I (hsTnI) is inappropriately studied. This study aimed to investigate the prognostic relevance of hsTnI in normotensive PE, establish the optimal cut-off value for risk stratification and to compare the prognostic performances of hsTnI and hsTnT. Based on data from 459 consecutive PE patients enrolled in a single-centre registry, receiver operating characteristic analysis was used to identify an optimal hsTnI cut-off value for prediction of in-hospital adverse outcomes (PE-related death, cardiopulmonary resuscitation or vasopressor treatment) and all-cause mortality. Patients who suffered an in-hospital adverse outcome (4.8%) had higher hsTnI concentrations compared with those with a favourable clinical course (57 (interquartile range (IQR) 22-197)

Informations de copyright

Copyright ©ERS 2020.

Déclaration de conflit d'intérêts

Conflict of interest: M. Ebner has nothing to disclose. Conflict of interest: N. Guddat has nothing to disclose. Conflict of interest: K. Keller has nothing to disclose. Conflict of interest: M.C. Merten has nothing to disclose. Conflict of interest: M.H. Lerchbaumer reports personal fees from Siemens Healthineers outside the submitted work. Conflict of interest: G. Hasenfuß reports personal fees from AstraZeneca, Berlin Chemie, Corvia, Impulse Dynamics, Novartis, Servier, Vifor Pharma and Springer International Publishing AG outside the submitted work. Conflict of interest: S.V. Konstantinides reports a grant from the German Federal Ministry of Education and Research (BMBF 01EO1503) during the conduct of the study; grants and personal fees from Bayer, Boehringer Ingelheim and Daiichi-Sankyo, personal fees from MSD, grants and personal fees from Pfizer–Bristol-Myers Squibb, and grants from Actelion, outside the submitted work. Conflict of interest: M. Lankeit reports grants from the German Federal Ministry of Education and Research (BMBF 01EO1503) and grants from BRAHMS GmbH, part of Thermo Fisher Scientific, during the conduct of the study; and personal fees from Actelion, Bayer, Daiichi-Sankyo, MSD, Pfizer–Bristol-Myers Squibb and BRAHMS GmbH outside the submitted work.